Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 303


Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease.

Dandapat S, Robinson JG.

Curr Neurol Neurosci Rep. 2016 Mar;16(3):24. doi: 10.1007/s11910-016-0621-1. Review.


Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.

Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U, Tershakovec AM, Braunwald E.

J Am Coll Cardiol. 2016 Feb 2;67(4):353-61. doi: 10.1016/j.jacc.2015.10.077.


Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E.

Circulation. 2015 Sep 29;132(13):1224-33. doi: 10.1161/CIRCULATIONAHA.115.018381. Epub 2015 Sep 1.


Clinical Impact of Rapid Reduction of Low-Density Lipoprotein Cholesterol Level on Long-Term Outcome of Acute Myocardial Infarction in the Statin Era: Subanalysis of the ALPS-AMI Study.

Miura T, Izawa A, Motoki H, Miyashita Y, Kashima Y, Ebisawa S, Tomita T, Koyama J, Ikeda U.

PLoS One. 2015 Jun 17;10(6):e0127835. doi: 10.1371/journal.pone.0127835. eCollection 2015.


Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.


National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV.

J Clin Lipidol. 2015 Mar-Apr;9(2):129-69. doi: 10.1016/j.jacl.2015.02.003. Epub 2015 Apr 7.


New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory.

Packard CJ, Weintraub WS, Laufs U.

Vascul Pharmacol. 2015 Aug;71:37-9. doi: 10.1016/j.vph.2015.03.008. Epub 2015 Apr 16. Review.


Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry).

O'Brien EC, Simon DN, Roe MT, Wang TY, Peterson ED, Alexander KP.

Am J Cardiol. 2015 Jun 15;115(12):1655-60. doi: 10.1016/j.amjcard.2015.03.007. Epub 2015 Mar 23.


Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.

Bangalore S, Breazna A, DeMicco DA, Wun CC, Messerli FH; TNT Steering Committee and Investigators.

J Am Coll Cardiol. 2015 Apr 21;65(15):1539-48. doi: 10.1016/j.jacc.2015.02.017.


The new dyslipidemia guidelines: what is the debate?

Anderson TJ, Mancini GB, Genest J Jr, Grégoire J, Lonn EM, Hegele RA.

Can J Cardiol. 2015 May;31(5):605-12. doi: 10.1016/j.cjca.2014.11.007. Epub 2014 Nov 11. Review.


The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.

Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ.

Eur Heart J. 2015 Jun 21;36(24):1536-46. doi: 10.1093/eurheartj/ehv072. Epub 2015 Mar 23. Review.


Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA).

Roberts ET, Horne A, Martin SS, Blaha MJ, Blankstein R, Budoff MJ, Sibley C, Polak JF, Frick KD, Blumenthal RS, Nasir K.

PLoS One. 2015 Mar 18;10(3):e0116377. doi: 10.1371/journal.pone.0116377. eCollection 2015.


Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge.

Rysz J, Gluba-Brzózka A, Banach M, Więcek A.

Int Urol Nephrol. 2015 May;47(5):805-13. doi: 10.1007/s11255-015-0937-9. Epub 2015 Mar 11. Review.


The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease.

Toth PP, Thanassoulis G, Williams K, Furberg CD, Sniderman A.

J Clin Lipidol. 2014 Nov-Dec;8(6):594-605. doi: 10.1016/j.jacl.2014.08.004. Epub 2014 Aug 30.


High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus.

Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP.

J Diabetes Complications. 2015 Jan-Feb;29(1):142-5. doi: 10.1016/j.jdiacomp.2014.10.004. Epub 2014 Oct 13. Review.


What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?

Santos RD.

Atheroscler Suppl. 2014 Sep;15(2):19-25. doi: 10.1016/j.atherosclerosissup.2014.07.003. Review.


Update on the NCEP ATP-III emerging cardiometabolic risk factors.

Eckel RH, Cornier MA.

BMC Med. 2014 Aug 26;12:115. doi: 10.1186/1741-7015-12-115. Review.


Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey.

Heuschmann PU, Kircher J, Nowe T, Dittrich R, Reiner Z, Cifkova R, Malojcic B, Mayer O, Bruthans J, Wloch-Kopec D, Prugger C, Heidrich J, Keil U.

Eur J Prev Cardiol. 2015 Oct;22(10):1354-62. doi: 10.1177/2047487314546825. Epub 2014 Aug 19.


LDL cholesterol: controversies and future therapeutic directions.

Ridker PM.

Lancet. 2014 Aug 16;384(9943):607-17. doi: 10.1016/S0140-6736(14)61009-6. Review.


Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.

Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, Reist C, McCagg A, Braunwald E, Califf RM.

Am Heart J. 2014 Aug;168(2):205-12.e1. doi: 10.1016/j.ahj.2014.05.004. Epub 2014 May 15.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk